XSTO
BICO
Market cap257mUSD
Jun 11, Last price
35.56SEK
1D
-2.58%
1Q
-6.42%
Jan 2017
70.35%
IPO
154.00%
Name
BICO Group AB
Chart & Performance
P/E
—
P/S
1.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.96%
Rev. gr., 5y
179.25%
Revenues
2.24b
+78.12%
Net income
-836m
L+264.62%
CFO
-269m
L-34.16%
Earnings
Aug 18, 2025
Profile
BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑08 | 2019‑08 | 2018‑08 | 2017‑08 | 2016‑08 | |
| Income | |||||||
Revenues | 2,239,500 78.12% | ||||||
Cost of revenue | 1,127,900 | ||||||
Unusual Expense (Income) | |||||||
NOPBT | 1,111,600 | ||||||
NOPBT Margin | 49.64% | ||||||
Operating Taxes | 82,600 | ||||||
Tax Rate | 7.43% | ||||||
NOPAT | 1,029,000 | ||||||
Net income | (835,700) 264.62% | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 540,600 | ||||||
BB yield | -7.64% | ||||||
| Debt | |||||||
Debt current | 97,700 | ||||||
Long-term debt | 2,215,600 | ||||||
Deferred revenue | |||||||
Other long-term liabilities | 224,600 | ||||||
Net debt | 1,388,100 | ||||||
| Cash flow | |||||||
Cash from operating activities | (269,400) | ||||||
CAPEX | (529,600) | ||||||
Cash from investing activities | 212,900 | ||||||
Cash from financing activities | 455,300 | ||||||
FCF | (84,800) | ||||||
| Balance | |||||||
Cash | 925,200 | ||||||
Long term investments | |||||||
Excess cash | 813,225 | ||||||
Stockholders' equity | (1,077,600) | ||||||
Invested Capital | 10,037,700 | ||||||
ROIC | 10.78% | ||||||
ROCE | 11.95% | ||||||
| EV | |||||||
Common stock shares outstanding | 66,877 | ||||||
Price | 105.80 -61.92% | ||||||
Market cap | 7,075,570 -58.49% | ||||||
EV | 8,490,870 | ||||||
EBITDA | 2,052,200 | ||||||
EV/EBITDA | 4.14 | ||||||
Interest | 98,200 | ||||||
Interest/NOPBT | 8.83% | ||||||